Genetic variants in CYP2C9 and VKORC1 strongly affect steady-state warfarin dose.
Introduction
Oral anticoagulation with warfarin is the most common therapy for the treatment and prevention of thromboembolic events. However, warfarin therapy is associated with considerable morbidity and mortality because it has a narrow therapeutic range and at least 10-fold interindividual variability in drug sensitivity. Warfarin therapy is monitored and the dose adjusted according to its pharmacodynamic effects on clotting, measured as the international normalized ratio (INR). The INR value is closely related to the risk of thrombosis with underanticoagulation, and that of bleeding with overanticoagulation. [1] [2] [3] Warfarin therapy is usually started with initial doses of 5-10 mg on the first two to three days, and subsequently titrated according to the INR response with the goal of achieving an INR within the therapeutic range within 4-6 days. 3 Since warfarin dose requirements vary widely, this standard regimen often results in subtherapeutic INR values in more resistant patients, and overshooting the therapeutic range in more sensitive patients. The risk of adverse effects associated with over-anticoagulation is high, especially in the first few weeks of therapy. 2;4;5 Therefore, strategies to individualize the initial warfarin dose have been sought.
Several factors are associated with an individual's sensitivity to warfarin, and thus the dose required for stable anticoagulation. These include age, ethnicity, comorbidities, concomitant medication, and genetic variation. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Two genes have been extensively studied: CYP2C9, encoding the enzyme (cytochrome P450 2C9) primarily responsible for the metabolism of the more active S-enantiomer of warfarin, and VKORC1, encoding the subunit 1 of the vitamin K epoxide reductase complex, the target of warfarin. Variants in these two genes affect warfarin dose requirements at steady state substantially; 6-17;20;21 For personal use only. on . by guest www.bloodjournal.org From moreover, at the start of warfarin therapy, VKORC1 and, to a lesser extent, CYP2C9 genotypes also affect early INR responses. 22;23 The clinically useful contribution of genotype to individualizing warfarin dose will likely be greatest in the initiation phase of therapy, before an individual's dose requirement has been determined empirically by titration according to INR response.
However, the genetic contribution to warfarin dose requirements has most often been studied using steady-state dose requirements in patients already receiving stable doses of warfarin, without considering the information provided by the early INR responses during initiation of warfarin therapy. In fact, in a recent study in orthopedic patients starting genotype-guided warfarin therapy, VKORC1 genotype did not contribute significantly to the prediction of early stable warfarin dose when the INR value on the 4 th day of treatment was included in the prediction model. 24 In 2007, the Food and Drug Administration updated the warfarin label to include information for prescribers about genotype, 25 To assess the effect of early INR response and genotypes on the outcomes, we performed Cox regression analyses to determine the hazard ratio (HR) of achieving (1) 
Results

Subject characteristics
Of 325 patients who met the inclusion criteria, 297 patients were recruited, 22 81 of whom were excluded from analysis since they did not have an INR value recorded on days 4-6, and two were excluded because they were neither African-American nor Caucasian. Demographic and clinical data for the remaining 214 patients are presented in Table 1 . For 210 patients (98%), the target INR range was between 1.7 and 3.0. Demographic, clinical, and genotype data for the excluded patients did not differ significantly from the included patients except a small difference in target INR (mean difference, 0.11; 95% CI, 0.07 to 0.15; P<0.001).
Genotyping results VKORC1 and CYP2C9 genotype could not be determined in one and two subjects, respectively. Allele frequencies were in the range expected for the respective ethnic group, and genotype distributions conformed to Hardy-Weinberg equilibrium ( Table 2) . Table 3 Clinical variables would not have predicted this sensitivity to warfarin. Yet, all four patients were carriers of genetic variants conferring increased sensitivity; thus, genotypeguided dosing may well have reduced the risk of overanticoagulation in these subjects.
Early INR values and outcomes
Our study has a number of strengths, including the combination of a number of outcomes with potential clinical relevance to assess warfarin sensitivity, a heterogeneous study population in a real-life environment treated with similar warfarin starting doses, and a systematic statistical analysis of the predictive value of different variables for the
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assessment of warfarin sensitivity. As expected in an observational study, not all patients had INR determined on the same day, and dosing was regulated by different clinics. As we have pointed out, variability in management is likely to favor the contribution of genotype, thus enhancing the relevance of our findings. Additionally, our study focuses on the induction phase of warfarin therapy and thus does not provide information about the predictive value of genotyping and early INR measurements on stability during longterm anticoagulation.
In conclusion, in this observational study much of the information provided by CYP2C9 and VKORC1 genotype about warfarin sensitivity was captured by the early INR response. Prospective studies on the value of genotype-guided warfarin initiation should be evaluated against the background of the study's setting, and include algorithms that incorporate early INR response. n/a n/a n/a INR week1 ** n/a n/a n/a -1. 
